Ramon Yitzhack, Fodor Lucian, Ullmann Yehuda
Department of Aesthetic Surgery, Elisha Hospital, Haifa, Israel.
Dermatology. 2007;214(2):151-4. doi: 10.1159/000098575.
Highly active antiretroviral therapy for HIV-infected patients causes metabolic changes known as the lipodystrophy syndrome. Autologous fat injections, dermal fat grafts, malar implants and injected fillers have been reported as treatment options.
To evaluate the results of HIV-infected patients treated with Bio-Alcamid for facial lipoatrophy.
Over a 3-year period, 13 HIV-infected patients with facial lipoatrophy had Bio-Alcamid injections for aesthetic purposes. The procedure was done under local anesthesia, and the amount of the injected material varied from 5 to 13 ml. Results were independently evaluated by patients and physicians.
Most of the patients felt they had good to excellent results. Touch-ups were necessary for 2 patients; the added volume was 2-3 ml for each. No major complications were recorded. A small hematoma was noted in 1 patient. Overcorrection was attained in 2 cases, and some of the filler was removed at the patient's request.
One of the greatest advantages of this filler is that, although permanent, it can be removed easily. We consider Bio-Alcamid to be a safe and useful correcting tool for patients suffering from drug-induced facial lipoatrophy.
针对感染HIV的患者的高效抗逆转录病毒疗法会引发被称为脂肪代谢障碍综合征的代谢变化。自体脂肪注射、真皮脂肪移植、颧骨植入物和注射填充剂已被报道为治疗选择。
评估使用Bio-Alcamid治疗HIV感染患者面部脂肪萎缩的效果。
在3年期间，13名患有面部脂肪萎缩的HIV感染患者出于美学目的接受了Bio-Alcamid注射。该操作在局部麻醉下进行，注射材料的量从5毫升到13毫升不等。结果由患者和医生独立评估。
大多数患者认为效果良好至极佳。2名患者需要进行补注；每次补注量为2至3毫升。未记录到重大并发症。1名患者出现小血肿。2例出现过度矫正，应患者要求取出了部分填充剂。
这种填充剂最大的优点之一是，尽管它是永久性的，但可以轻松取出。我们认为Bio-Alcamid对于患有药物性面部脂肪萎缩的患者来说是一种安全且有用的矫正工具。
